Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012

Velde, Cornelis J.H. van de; Boelens, Petra G.; Tanis, Pieter J.; Espín, Eloy; Mroczkowski, Paweł; Naredi, Peter; Påhlman, Lars; Ortiz, Héctor; Rutten, H.J.T.; Breugom, A.J.; Smith, Jason; Wibe, Arne; Wiggers, Theo; Valentini, Vincenzo

doi:10.1016/j.ejso.2013.10.013

Cited by 61 publications

(32 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However CRC is still an important cause of cancer related death. Research groups are focused on understanding the risk factors, molecular biology, and genetics of CRC and also developing new drugs and drug combinations for the management of this deadly disease (van de Velde et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells

Kaya¹,

Altun²,

Turgut³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

In the present study, we investigated the effects of motesanib (AMG 706), a multikinase inhibitor alone and in combination with DuP-697, an irreversible selective inhibitor of COX-2, on cell proliferation, angiogenesis, and apoptosis induction in a human colorectal cancer cell line (HT29). Real time cell analysis (RTCA, Xcelligence system) was used to determine the effects on colorectal cancer cell proliferation. Apoptosis was assessed with annexin V staining and angiogenesis was determined with chorioallantoic membrane model. We found that motesanib alone exerted antiproliferative, antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. Combination with DUP-697 increased the antiproliferative, antiangiogenic and apoptotic effects. Results of this study indicate that motesanib may be a good choice in treatment of colorectal tumors. In addition, the increased effects of combination of motesanib with DuP-697 raise the possibility of using lower doses of these drugs and therefore avoid/minimize the dose-dependent side effects generally observed.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells

Kaya¹,

Altun²,

Turgut³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…below 70 years of age without significant co-morbidities), acute resection should be considered as standard of care. For patients not suitable for stenting and with a high operative risk, diverting colostomy is a suitable treatment option [1]. In our series, the high proportion of curative intent surgeries (81.1%), specially in colon cancer patients (86.5%), helps to justify the low proportion of stent placements.…”

Section: Discussionmentioning

confidence: 89%

“…Currently, surgical outcome and quality of cancer care are at the top of the list of "improvement of care" projects. From large observational research, we know that wide variations in patterns of care and outcome exist in the field of surgical oncology [1].…”

Section: Introductionmentioning

confidence: 99%

Colorectal Cancer Surgery in Extreme Elderly Population

Plazas¹,

Asensio²,

Navalón³

et al. 2015

JCT

View full text Add to dashboard Cite

“…1 As a result, a growing number of surgical patients are admitted to intensive care units, and are fast becoming the predominant patient population in this setting. 2 Beds in intensive care units are limited and expensive.…”

Section: Introductionmentioning

confidence: 99%

Analysis of factors conditioning admission at the critical care unit of surgical patients. Prospective study of 764 patients operated for 1 year at a university and reference hospital

Bona

Bellosta

Cabrera

et al. 2015

Revista Española de Anestesiología y Reanimación (English Editi

View full text Add to dashboard Cite

Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012

Cited by 61 publications

References 131 publications

Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells

Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells

Colorectal Cancer Surgery in Extreme Elderly Population

Analysis of factors conditioning admission at the critical care unit of surgical patients. Prospective study of 764 patients operated for 1 year at a university and reference hospital

Contact Info

Product

Resources

About